2 weeks Ago By ABMN Staff
American Century Companies Inc. raised its stake in shares of Xencor, Inc. ( NASDAQ:XNCR – Free Report ) by 14.
5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 95,375 shares of the biopharmaceutical company’s stock after buying an additional 12,083 shares during the quarter. American Century Companies Inc.
’s holdings in Xencor were worth $1,805,000 at the end of the most recent reporting period. A number of other institutional investors and hedge funds also recently modified their holdings of XNCR. Vanguard Group Inc.
grew its stake in Xencor by 3.6% in the first quarter. Vanguard Group Inc.
now owns 7,011,042 shares of the biopharmaceutical company’s stock valued at $155,154,000 after acquiring an additional 243,793 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Xencor by 9.
6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock valued at $84,530,000 after purchasing an additional 335,881 shares during the period.
Armistice Capital LLC increased its stake in Xencor by 1.5% during the 4th quarter. Armistice Capital LLC now owns 1,500,000 shares of the biopharmaceutical company’s stock worth $31,845,000 after purchasing an additional 22,000 shares in the last quarter.
Darwin Global Management Ltd. acquired a new stake in Xencor during the 1st quarter worth approximately $24,557,000. Finally, Baker BROS.
Advisors LP lifted its stake in Xencor by 122.2% in the first quarter. Baker BROS.
Advisors LP now owns 545,431 shares of the biopharmaceutical company’s stock valued at $12,070,000 after buying an additional 300,000 shares in the last quarter. Insider Transactions at Xencor In related news, VP John R. Desjarlais sold 36,329 shares of the company’s stock in a transaction dated Tuesday, July 9th.
The shares were sold at an average price of $18.32, for a total value of $665,547.28.
Following the transaction, the vice president now owns 192,319 shares in the company, valued at approximately $3,523,284.08. The sale was disclosed in a document filed with the SEC, which can be accessed through this link .
5.23% of the stock is currently owned by corporate insiders. Wall Street Analyst Weigh In Read Our Latest Analysis on Xencor Xencor Stock Performance Shares of XNCR stock opened at $20.
25 on Monday. The stock has a market cap of $1.25 billion, a P/E ratio of -9.
25 and a beta of 0.66. The company has a debt-to-equity ratio of 0.
02, a current ratio of 6.92 and a quick ratio of 6.92.
The company has a fifty day moving average price of $18.63 and a two-hundred day moving average price of $20.32.
Xencor, Inc. has a one year low of $15.31 and a one year high of $26.
84. Xencor ( NASDAQ:XNCR – Get Free Report ) last announced its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.
07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.25).
Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%.
The business had revenue of $16.96 million for the quarter, compared to analyst estimates of $21.13 million.
During the same period in the prior year, the business earned ($0.37) EPS. The company’s revenue for the quarter was down 62.
7% compared to the same quarter last year. As a group, equities analysts predict that Xencor, Inc. will post -4.
15 EPS for the current year. About Xencor ( Free Report ) Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Featured Stories Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. ( NASDAQ:XNCR – Free Report ).
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter ..
